Based on these encouraging data, GSK also announced today the opening of patient recruitment to the randomized and controlled Phase III efficacy and safety trial for this novel cancer immunotherapy, the largest clinical trial ever conducted in lung cancer MAGE-A3 ASCI as adjuvant therapy in about 2,270 MAGE-A3-positive patients will be assessed with completely resected stage IB, II or IIIA NSCLC.
James Dudley Endowed Professor of Oncology, specially designed Medicine and Director of the University of Colorado Cancer Center, Colorado. This approach provides a potentially significant shift in the cancer treatment paradigm. I think we have only scratched the surface of what is possible and look forward to the results of the Phase III study in the course. .. Final results of this trial confirm the positive interim results published last year expanded at ASCO 2006 , and support testing of this novel cancer immunotherapy, said Paul A. Bunn Jr. (more…)